Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35992
Title: | Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. | Authors: | Cheah C.Y.;Marlton P.;Trotman J.;Opat S. | Institution: | (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia (Cheah) Department of Haematology, Pathwest Laboratory Medicine WA, WA, Australia (Cheah) Medical School of Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia (Opat) Clinical Haematology and School of Clinical Sciences, Monash Health, Clayton, VIC, Australia (Opat) Department of Medicine, Monash University, Melbourne, VIC, Australia (Trotman) Department of Haematology, Concord Hospital, Sydney, NSW, Australia (Trotman) Department of Medicine, University of Sydney, Sydney, NSW, Australia (Marlton) Division of Cancer Services, Clinical Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia (Marlton) University of Queensland School of Medicine, Brisbane, QLD, Australia | Issue Date: | 19-Oct-2019 | Copyright year: | 2019 | Publisher: | Blackwell Publishing | Place of publication: | Australia | Publication information: | Internal Medicine Journal. 49 (9) (pp 1070-1080), 2019. Date of Publication: 01 Sep 2019. | Journal: | Internal Medicine Journal | Abstract: | Mantle cell lymphoma (MCL) and the marginal zone lymphoma (MZL) subtypes (nodal MZL, extra-nodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma) and splenic MZL) are uncommon lymphoma subtypes, accounting for less than 5-10% of all non-Hodgkin lymphoma. The evidence base for therapy is therefore limited and enrolment into clinical trials is preferred. Outcomes for patients with MCL have been steadily improving mainly due to the adoption of more intense strategies in younger patients, the use of rituximab maintenance and the recent introduction of bendamustine in older patients. MZL is a more heterogeneous group of cancer with both nodal, extra-nodal and splenic subtypes. Extranodal MZL may be associated with autoimmune or infectious aetiologies, and can respond to eradication of the causative pathogen. Proton pump inhibitor plus dual antibiotics in Helicobacter pylori positive gastric MALT lymphoma is curative in many patients. Watchful waiting is appropriate in most patients with asymptomatic advanced stage disease, which tends to behave in a particularly indolent manner. Other options for symptomatic disease include splenectomy, chemoimmunotherapy with rituximab and, more recently, targeted therapies.Copyright © 2019 Royal Australasian College of Physicians | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/imj.14268 | PubMed URL: | 30816618 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30816618] | ISSN: | 1444-0903 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35992 | Type: | Review | Subjects: | positron emission tomography cancer prognosis cancer recurrence cancer staging cancer survival Chlamydia psittaci computer assisted tomography drug effect drug targeting event free survival fluorescence in situ hybridization Helicobacter pylori Hepatitis C virus human *mantle cell lymphoma/di [Diagnosis] *mantle cell lymphoma/dt [Drug Therapy] *marginal zone lymphoma/di [Diagnosis] *marginal zone lymphoma/dt [Drug Therapy] multiple cycle treatment nonhuman overall survival priority journal progression free survival review survival time treatment duration treatment outcome treatment planning tumor biopsy bendamustine/cb [Drug Combination] bendamustine/dt [Drug Therapy] cyclophosphamide/cb [Drug Combination] cyclophosphamide/dt [Drug Therapy] cytarabine/dt [Drug Therapy] doxorubicin/cb [Drug Combination] doxorubicin/dt [Drug Therapy] fludarabine/cb [Drug Combination] fludarabine/dt [Drug Therapy] methotrexate/cb [Drug Combination] methotrexate/dt [Drug Therapy] prednisolone/cb [Drug Combination] prednisolone/dt [Drug Therapy] prednisone/cb [Drug Combination] prednisone/dt [Drug Therapy] rituximab/cb [Drug Combination] rituximab/dt [Drug Therapy] vincristine/cb [Drug Combination] vincristine/dt [Drug Therapy] Australia Borrelia burgdorferi Campylobacter jejuni cancer combination chemotherapy cancer immunotherapy Chlamydia psittaci computer assisted tomography drug effect drug targeting event free survival fluorescence in situ hybridization Helicobacter pylori Hepatitis C virus human *mantle cell lymphoma / *diagnosis / *drug therapy *marginal zone lymphoma / *diagnosis / *drug therapy multiple cycle treatment nonhuman overall survival positron emission tomography priority journal progression free survival Review treatment duration treatment outcome tumor biopsy survival time Australia Borrelia burgdorferi Campylobacter jejuni cancer combination chemotherapy cancer immunotherapy cancer prognosis cancer recurrence cancer staging cancer survival treatment planning |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.